Signalling molecules - Lectures

Prediction of the efficacy of mTOR targeted therapies

Pathway Driven Approaches

Pathways triggered by FGF and other growth factors

Pathway Driven Approaches

Phenotypic Signaling Pathway Characterization in Complex Cell Populations for Treatment Selection and Response Assessment

Biomarkers for Antitumour Evaluation

A First-in-Human Phase I Monotherapy Study of RG7212 (R), a Novel Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Solid Tumors

Proffered Paper Session

Agents targeting the mTOR-PI3K-Akt pathway

Keynote Lecture

The role of JAK-2 inhibition

Hematological disorders

Akt and Ras pathways and modulation of TF expression in glioblastoma

Genomics and proteomics of the hemostatic system in cancer

Classical Hodgkin Lymphoma Microenvironment. Pathologic Aspects and the Role of CD40 / CD40L

Lymphoma Microenvironment

Clinical and biological efficacy to anti-TNF therapy relates to reciprocally modulating blood and intestinal mucosa Foxp3 expression

It's not always IBD

Modulation of gut immune homeostasis via the Toll-interacting protein

Extraintestinal manifestations

Oxygen sensor inhibition attenuates TNF-?-induced intestinal epithelial damage by hypoxia-inducible factor (HIF)-1-dependent repression of fas-associated death domain protein (FADD)

Fibrogenesis and its consequences